EYPT
EyePoint Pharmaceuticals, Inc.
EYPT
EyePoint Pharmaceuticals, Inc.
EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
RADNOR, Pa., Sept. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the feder
RADNOR, Pa., Aug. 28, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the feder
Eyepoint Pharmaceuticals (EYPT) plunged 70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort. EYPT's management argues the failure was driv
EyePoint Pharmaceuticals approaches a binary valuation inflection with pivotal Phase III LUGANO data for DURAVYU in wet AMD due August 2026. EYPT's clinical program emphasizes repeat six-month dosing,